Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
| Autor: | Knop, Filip K *, Aroda, Vanita R, do Vale, Ruben D, Holst-Hansen, Thomas, Laursen, Peter N, Rosenstock, Julio, Rubino, Domenica M, Garvey, W Timothy |
|---|---|
| Zdroj: | In The Lancet 26 August-1 September 2023 402(10403):705-719 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|